Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective ...

Explore innovative nutritional and microbial strategies for effectively treating acne, alopecia, and atopic dermatitis.

The Phase III ECZTEND study reported that patients treated with Adbry demonstrated long term safety and efficacy for up to ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened ...

Individuals who suffer from atopic dermatitis are three times more likely to develop anxiety, depression and sleep ...

Positive results were announced from the ECZTEND extension study of Adbry in atopic dermatitis who took part in a previous parent trial.

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

These guidelines, published in 2023, arose due to the emergence of new evidence since the AAD’s 2014 atopic dermatitis guidelines that further informs the management of AD with systemic agents, and ...

Researchers recently identified five extrapulmonary treatable traits in asthma that are clinically relevant and have a clear ...